SCHEMBL4923925

SCHEMBL4923925

CC1(C)Cc2cscc2C(=O)N1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 3/20 0.54
HPGD P15428 3/20 0.51
HSD17B10 Q99714 2/20 0.51
GFER P55789 1/20 0.51
ALDH1A1 P00352 3/20 0.41
KDM4E B2RXH2 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C19 P33261 1/20 0.41
CDK5 Q00535 1/20 0.41
CDK5R1 Q15078 1/20 0.41
NCOA1 Q15788 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
NCOA3 Q9Y6Q9 1/20 0.41
CDC7 O00311 2/20 0.40
ALOX15 P16050 1/20 0.36
NPSR1 Q6W5P4 1/20 0.33
TSHR P16473 1/20 0.33
BUB1 O43683 1/20 0.33
KMT2A Q03164 1/20 0.32
MAPT P10636 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4842012 0.72 NPSR1 (0.62) HTTHPGDHSD17B10GFERALDH1A1
SCHEMBL4922973 0.69 ALDH1A1 (0.44) HTTALDH1A1KDM4ECYP2C19KMT2A
SCHEMBL4845197 0.68 HPGD (1.00) HTTHPGDHSD17B10GFERALDH1A1
SCHEMBL21768055 0.67 HTT (0.58) HTTHPGDHSD17B10GFERALDH1A1
SCHEMBL22782798 0.67 HTT (0.58) HTTHPGDHSD17B10GFERALDH1A1
SCHEMBL6434186 0.67 HTT (0.46) HTTHPGDHSD17B10GFERALDH1A1
SCHEMBL21768027 0.65 HTT (0.55) HTTHPGDHSD17B10GFERALDH1A1
SCHEMBL4929490 0.65 HTT (0.41) HTTHPGDHSD17B10GFERALDH1A1
SCHEMBL7505165 0.65 HPGD (0.60) HTTHPGDHSD17B10GFERALDH1A1
SCHEMBL25209666 0.63 CDC7 (0.47) HTTHPGDHSD17B10GFERALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080275066-A1 Condensed Thiophene Derivatives and Their Use as Cyclic Glp-1 Agonists NOVO NORDISK A/S (DK) 2008-11-06 US disclosed
US-20080275066-A1 Condensed Thiophene Derivatives and Their Use as Cyclic Glp-1 Agonists NOVO NORDISK A/S (DK) 2008-11-06 US disclosed
US-20080275066-A1 Condensed Thiophene Derivatives and Their Use as Cyclic Glp-1 Agonists NOVO NORDISK A/S (DK) 2008-11-06 US disclosed
EP-1765814-A1 CONDENSED THIOPHENE DERIVATIVES AND THEIR USE AS CYCLIC GLP-1 AGONISTS NOVO NORDISK A/S (DK) 2007-03-28 EP disclosed
WO-2006003096-A1 CONDENSED THIOPHENE DERIVATIVES AND THEIR USE AS CYCLIC GLP-1 AGONISTS NOVO NORDISK A/S (DK) 2006-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275066-A1 Condensed Thiophene Derivatives and Their Use as Cyclic Glp-1 Agonists GLP1R, GIPR, GCGR HTT 1557/4885HPGD 1769/4885HSD17B10 1766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.